| Trial ID: | L4628 |
| Source ID: | NCT00241423
|
| Associated Drug: |
Exenatide
|
| Title: |
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: exenatide|DRUG: Placebo
|
| Outcome Measures: |
Primary: Time-averaged serum glucose during a 24-hour period, Time-averaged serum glucose during a 24-hour period, Every half-hour to hour for 24 hours | Secondary: To compare the effects of exenatide and placebo on serum glucose, To compare the effects of exenatide and placebo on serum glucose measured as averaged daytime glucose, averaged nighttime glucose, time-averaged postprandial glucose 2 hours after each meal, time-averaged postprandial glucose 4 hours after each meal, 2-hour postprandial glucose averaged across morning and evening meals, and averaged across the three meals, and fluctuation evaluations, Each half-hour to 2 hours for 24 hours
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-10
|
| Completion Date: |
2007-06
|
| Results First Posted: |
|
| Last Update Posted: |
2015-02-23
|
| Locations: |
Research Site, Washington, District of Columbia, United States|Research Site, San Antonio, Texas, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00241423
|
